UK markets closed

Renalytix Plc (RNLX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.7001-0.0589 (-7.76%)
At close: 04:00PM EDT
0.7054 +0.01 (+0.76%)
After hours: 07:13PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7590
Open0.7711
Bid0.6756 x 300
Ask0.7355 x 400
Day's range0.6310 - 0.7952
52-week range0.2450 - 4.0380
Volume217,898
Avg. volume2,009,648
Market cap51.795M
Beta (5Y monthly)1.91
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Pentwater Capital Management LP - Form 8.3 - Renalytix PLC

    Pentwater Capital Management LP - Form 8.3 - Renalytix PLC

  • Globe Newswire

    Renalytix Announces Financing with Expected Size of up to $4 Million

    LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseas

  • Globe Newswire

    KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

    Guidelines highlight the importance of risk prediction and personalized treatment to reduce riskLONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024. In the release of the n